Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies
Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies presents a description of the sensitizers used to overcome resistance to anti-EGFR targeted antibody therapies in cancer, including novel engineered antibody drugs and other sensitizers. The book...
Leider schon ausverkauft
232.99 €
versandkostenfrei
116 DeutschlandCard Punkte
sammeln
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenlose Rücksendung
- Ratenzahlung möglich
Produktdetails
Produktinformationen zu „Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies “
Weitere Produktinformationen zu „Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies “
Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies presents a description of the sensitizers used to overcome resistance to anti-EGFR targeted antibody therapies in cancer, including novel engineered antibody drugs and other sensitizers. The book gives insights into the landscape of anti-EGFR based cancer treatments, the challenges of targeted therapy, and a glimpse into the future of antibody therapy. It offers pertinent science information on strategies used for the rational design and discovery of novel sensitizing agents, and in addition, translational studies involving pre-clinical and clinical design. This book is an indispensable resource for cancer researchers, medicinal chemists and other biomedical scientists.Finally, the book covers basic science strategies used in drug discovery and preclinical evaluation focused on EGFR blockage resistance, as well as clinical trial methodology, including clinical pharmacokinetics and imaging to address issues of efficacy evaluation of the new anticancer sensitizers for anti-EGFR drug resistance.
Bibliographische Angaben
- Herausgegeben:Hu, Shi
- Verlag: Academic Press
- EAN: 9780128215845
Autoren-Porträt
Dr. Shi Hu received an MD and a PhD in tumor immunology from Second Military Medical University, Shanghai, China. Since 2015, Dr. Hu leads a research laboratory in the Department of Biophysics, at second military medical university with a faculty position. His laboratory is interested in synthetic immunology based cancer therapeutics and antibody engineering, primarily development of novel sensitizers for antibody-based therapies (e.g., Anti-ERBB antibodies). Dr. Hu's research is currently supported by the National Natural Science Foundation of China.
Kommentar zu "Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies"
0 Gebrauchte Artikel zu „Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies“
| Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
|---|
Schreiben Sie einen Kommentar zu "Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies".
Kommentar verfassen